U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Tri-Med, Inc. dba Advanced Care Infusion-Shelby - 478092 - 05/02/2018
  1. Warning Letters

CLOSEOUT LETTER

Tri-Med, Inc. dba Advanced Care Infusion-Shelby MARCS-CMS 478092 —

Recipient:
Tri-Med, Inc. dba Advanced Care Infusion-Shelby

United States

Issuing Office:

United States

 

   

Black HHS-Blue FDA Logo

 

 
 
Division of Pharmaceutical Quality Operations III
300 River Place, Suite 5900
Detroit, MI 48207
Telephone: (313) 393-8100
Fax: (313) 393-8139 

May 2, 2018

UPS NEXT DAY
SIGNATURE REQUIRED

Dr. William C. Drake, PharmD
President
Tri-Med, Inc. dba Advanced Care Infusion-Shelby
39011 Harper Avenue
Clinton Township, MI 48036

Dear Dr. Drake:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter 2016-DET-04 dated December 18, 2015. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to assure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/

Nicholas F. Lyons
Director of Compliance
Division of Pharmaceutical Quality Operations III 

Back to Top